PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | C0024299|lymphoma |
| Sentences | 6 |
| PubMedID- 26472982 | breast cancer coexisting with lymphoma is a rare condition with various diagnostic and therapeutic implications. |
| PubMedID- 22275822 | In a phase i clinical study, lipo-dox achieved the most prolonged circulation half-life (65 hours).73 however, tseng et al demonstrated that there were no differences in survival between free doxorubicin only (median survival time of 23 days) and lipo-dox (medium survival time of 23.5 days) in a murine b-cell lymphoma model.74 in patients with metastatic breast cancer, the median time to disease progression of 163 days represented the result of lipo-dox treatment and the median duration of response in responding patients (286 days) are comparable with those of doxil treatment.75 neutropenia, stomatitis, and skin toxicity were reported in many cases of lipo-dox administration. |
| PubMedID- 24649217 | 4), followed by breast cancer, non-hodgkin’s lymphoma (nhl), liver, ovarian and colorectal cancer, leukemia, and stomach cancer, whereas in men, it is prostate cancer followed by other cancer types (fig. |
| PubMedID- 24598796 | The most significant association for follicular lymphoma was with a breast cancer risk variant [rs11249433 in embp1: summary or per allele c = 1.29 (1.08–1.54), p = 0.0095]. |
| PubMedID- 21475637 | Several reports have appeared illustrating the high association of breast cancer with subsequent lymphoma developing systemically 22. there have, in addition, been several situations reported where the association of the two pathologic processes has appeared in the same breast synchronously. |
| PubMedID- 22735172 | Generalized telangiectasia as the manifestation of intravascular large b-cell lymphoma complicated with breast cancer. |
Page: 1